Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458671 | 0.90 | GAA (0.45) | IP6K1PTPRC | |
| SCHEMBL2463213 | 0.84 | IP6K1 (0.42) | IP6K1CSF1RDRD4DRD2TP53 | |
| SCHEMBL2461832 | 0.84 | IP6K1 (0.42) | IP6K1PTPRC | |
| SCHEMBL1919963 | 0.80 | MAPT (0.48) | IP6K1TP53 | |
| SCHEMBL691990 | 0.78 | IP6K1 (0.47) | IP6K1CSF1RDRD2TP53 | |
| SCHEMBL2456136 | 0.78 | IP6K1 (0.36) | IP6K1DRD4PTPRC | |
| SCHEMBL2456132 | 0.77 | HDAC4 (0.42) | IP6K1 | |
| SCHEMBL3452434 | 0.76 | IP6K1 (0.42) | IP6K1CSF1R | |
| SCHEMBL2458654 | 0.76 | MAPT (0.46) | IP6K1 | |
| SCHEMBL2462006 | 0.75 | MAPT (0.45) | IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069315-B1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | ORGANON NV (NL) | 2011-09-07 | — | — | EP | disclosed |
| US-7820649-B2 | Quinazolinone and isoquinolinone acetamide derivatives | N.V. ORGANON (NL) | 2010-10-26 | — | — | US | disclosed |
| EP-2069315-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. Organon (NL) | 2009-06-17 | — | — | EP | disclosed |
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-04-17 | — | — | US | disclosed |
| WO-2008033764-A2 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | N.V. ORGANON (NL) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090802-A1 | QUINAZOLINONE AND ISOQUINOLINONE ACETAMIDE DERIVATIVES | NQO2, GATD3, SDHA | IP6K1 2048/4885ACHE 372/4885BACE1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.